Why VIVUS Inc. Is Falling Today

VIVUS Inc. is falling to multi-year lows in premarket today. Find out why.

Feb 25, 2014 at 9:32AM

VIVUS (NASDAQ:VVUS) reported earnings after the bell yesterday and its shares have been on a roller coaster ride ever since. Immediately following the release, shares rose over 4%, but have now fallen close to 13% in premarket trading this morning.

So, what's up?

Conference call takeaways
First the positive news. CEO Seth Fischer started off by announcing that the company has modified the design of Qsymia's postmarketing study in the U.S. to create a potential pathway to approval in Europe. As a refresher, Qsymia's application in Europe was rejected last year primarily due to a lack of long-term safety data. Per Mr. Fischer's comments, he said that they have received helpful feedback from EU officials regarding the kinds of safety data needed to move forward, and have submitted an amended protocol to the U.S. Food and Drug Administration, or FDA.

He also reminded investors that the commercialization of the company's erectile dysfunction drug Stendra is well under way, with multiple licensing deals in place with AuxiliumMenarini and Sanofi. These deals are worth up to $460 million in potential milestone payments, of which VIVUS has already received around $61 million.

Turning to the bad news, Qsymia revenues were negatively affected by the company's marketing efforts, namely free trial offers for the initial dose and the pay no more than $75 per month for up to three months offer. And even with these hefty promotional efforts in place, Qsymia prescriptions for 2013 still only came in around 124k. A quick look at the data made publicly available by Arena Pharmaceuticals (NASDAQ:ARNA) suggests that Belviq should easily beat Qsymia in terms of prescriptions written during the first year on the market. In short, Qsymia appears to be losing out against Belviq, despite having better efficacy. 

Getting down to actual earnings, VIVUS lost $17.2 million, or $0.17 net loss per share, in the fourth quarter of 2014. On the bright side, VIVUS was able to cut its net loss per share by 70% due to the licensing revenue from Stendra.

VIVUS also greatly improved its cash position, ending the year with $343.3 million in cash and cash equivalents as of Dec. 31, 2013. This is an increase of $128.7 million compared to a year ago, giving VIVUS a nice financial cushion for the time being. 

So, why are VIVUS shares so volatile post-earnings?

My view is that the Mr. Market first saw the 70% improvement in net losses as a positive. Indeed, this is a substantial improvement, but it's important to understand that this is solely the result of one-time charges, i.e., milestone payments. And future milestone payments for Stendra are not guaranteed, but rather tied to the drug's commercial performance.

By contrast, I think what bummed investors out is a question by Lee Kalowski, an analyst from Credit Suisse. Specifically, he asked why Qsymia prescription numbers have yet to rebound from the holiday season. To provide some context, VIVUS's management blamed Qsymia's flagging prescription numbers in the fourth quarter, earlier in the call, on the holiday season. Unfortunately, Mr. Fischer was unable to provide much insight into the issue, simply stating that numbers should pick up late in the quarter. 

Foolish final thoughts
Investors are clearly unhappy with VIVUS's earnings report yesterday, pushing the stock down to multi-year lows in premarket. That said, you need to understand that VIVUS is getting close to trading at a mere 2.5 times its cash position, a rare event in the biopharma space. And while the potential launch of two new obesity medications from Orexigen Therapeutics (NASDAQ:OREX) and Novo Nordisk could be yet another problem facing VIVUS, I have to wonder if this company is becoming so cheap that it might be an interesting acquisition target.

With Sarissa Capital intimately involved in VIVUS's dealings and their history of putting companies on the auction block, you shouldn't be surprised if an exit strategy is being mulled over by upper management. Indeed, a licensing deal for Qsymia would probably cost more than a buyout at this point for a larger pharma, especially if Arena and Orexigen's partnerships are any guide. However, trying to simply guess which companies big pharmas will acquire isn't a solid investment strategy for investors to follow.

Biotechs aren't the only way for growth investors to profit
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

George Budwell owns shares of Orexigen Therapeutics. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers